Background and objectives Cardiovascular disease is the most common cause of death in CKD. This study evaluated whether electrocardiogram (ECG) abnormalities are predictors of cardiovascular death in CKD.
Introduction
The prevalence of CKD among persons age 65 years and older is increasing; it was estimated at 7.6% in 2008, about five-fold higher than the prevalence of 1.7% reported in 1995 (1) . Cardiovascular disease is the most common cause of death in individuals with CKD (2) . In particular, there is a high incidence of sudden, presumed cardiac death in patients with CKD (3). CKD is recognized as an independent risk factor for cardiovascular disease and death (4) . For every 10 mL/min per 1.73 m 2 decline in GFR, there is a 5% higher cardiovascular risk (5) . Older patients have a much higher risk for developing or dying of cardiovascular disease than for progressing to ESRD (6) . Therefore, there has been significant interest in identifying subclinical cardiovascular disease and its outcomes in the setting of CKD (7) (8) (9) .
Electrocardiography is a readily available and inexpensive tool to assess the burden of cardiovascular disease. Although several studies have examined the cross-sectional association between electrocardiogram (ECG) abnormalities and CKD, there are limited data on the prevalence of ECG abnormalities and their association with longitudinal cardiovascular outcomes in patients with CKD, particularly in the elderly (6, (10) (11) (12) (13) (14) (15) . The purpose of our study was to assess the prevalence of significant ECG abnormalities and evaluate their association with subsequent cardiovascular morbidity and mortality in a large cohort of older adults with CKD enrolled in the Cardiovascular Health Study (CHS).
Materials and Methods

Study Population
CHS is a population-based, longitudinal study of coronary artery disease (CAD) and stroke in adults age 65 years and older, conducted by the National Heart, Lung, and Blood Institute. A total of 5888 participants were enrolled in the study starting in 1989 and have been followed to date. The study design, quality-control procedures, laboratory methods, and BP measurement procedures have been previously published (16) . To be eligible, participants had to be 65 years of age or older at the time of baseline examination, residing in the community, expected to remain in the area for the next 3 years, and able to give informed consent without requirement of a proxy. Persons who were wheelchair-dependent or receiving hospice treatment, radiation therapy, or chemotherapy for cancer were excluded. The initial cohort of 2962 women and 2239 men was examined yearly from 
Ascertainment of ECG Abnormalities
Resting standard 12-lead ECGs were recorded at study entry using a MAC PC-DT Personal Cardiograph (Marquette Electronics Inc., Milwaukee, WI). The ECG abnormalities were identified using the Minnesota electrocardiography coding system (17) . They were classified into major and minor ECG abnormalities by CHS personnel. Major abnormalities were defined as ventricular conduction defect (Minnesota codes 7.l, 7.2, 7.4); major Q-wave abnormalities (codes 1. 
GFR Measurement
The measures of kidney function were serum creatinine and estimated GFR (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) study equation as follows: Serum creatinine was measured using the Kodak Ektachem 700 Analyzer (Eastman Kodak, Rochester, NY), a colorimetric method. For eGFR estimation, serum creatinine measurements were recalibrated to standardized creatinine measurements obtained at the Cleveland Clinic Research Laboratory, the core laboratory for the MDRD study, as previously described (18) . CKD was defined as eGFR , 60 ml/min per 1.73 m 2 on the basis of Kidney Disease Outcomes Quality Initiative criteria (19).
Definition of Clinical Variables
Participants were classified as hypertensive if they had hypertension as defined by the Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure criteria or if they were using antihypertensive medications (20) . Diabetes was defined by a history of diabetes, the use of antihyperglycemic medications, a glucose level $200 mg/dl at 2 hours after glucose load, or a fasting plasma glucose level $126 mg/dl.
Previous CAD was defined as a history of myocardial infarction, characterized by the presence of a major Q wave or a minor Q wave with ischemic ST-T changes or as selfreported history of physician-diagnosed CAD.
Fatal events were classified by a mortality review committee using information from death certificates; autopsy and coroner forms; hospital records; and interviews with attending physicians, next of kin, and witnesses.
Outcome Measures
The study outcome was time to cardiovascular death and time to first or first recurrence of cardiovascular events. For the cardiovascular mortality analysis, follow-up time was calculated from the time of the first visit to the date of death. Deaths were categorized as cardiovascular (mortality caused by CAD, heart failure, and cerebrovascular disease) or noncardiovascular. The mechanism of cardiac death was defined as primary arrhythmic, secondary arrhythmic, congestive heart failure, cardiac procedure, multiple causes, hemorrhage from thrombolytic therapy, or unknown. The CHS Events Subcommittee determined the cause of death for all fatal events and classified incident morbid events for the end points. The committee included CHS investigators from each of the four field centers, the coordinating center, and the project officer from the National Heart, Lung, and Blood Institute.
Participants were censored when they left the study or died of cardiovascular or noncardiovascular causes. Cardiovascular events were defined as both fatal and nonfatal myocardial infarction, stroke, congestive heart failure, angioplasty, coronary artery bypass surgery, and electrocardiographically defined silent myocardial infarction. For cardiovascular event analysis, follow-up time was calculated from the time of the baseline examination to the time of diagnosis of a first cardiovascular event for those with no history of a myocardial infarction and to the time of diagnosis of a recurrent cardiovascular event for those with a history of myocardial infarction. For participants who did not experience a cardiovascular event, follow-up ended on the date of last known contact or death. The studied population was followed for a mean 6 SD of 10.363.8 years.
Statistical Analyses
Continuous data are reported as means 6 SDs, and categorical data are reported as percentages. The prevalence of ECG abnormalities at study baseline was examined by eGFR dichotomized using 60 mL/min per 1.73 m 2 as a cutoff point for the diagnosis of CKD. After stratification, we evaluated baseline characteristics of participants by the type of ECG abnormalities and compared the groups using ANOVA. Logistic regression models were used to calculate the prevalence odds ratio of ECG abnormalities in CKD participants. Kaplan-Meier curves were plotted to compare the probability of death, cardiovascular events, and cardiovascular death for each group. Participants who died of noncardiovascular causes were censored at the date of death; participants who were lost to follow-up were censored at the date of last documented contact with the study center. We used Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for overall death, cardiovascular events, and cardiovascular death for each category, adjusting for age, race, gender, hypertension, diabetes, body mass index, smoking, b-blockers, angiotensin-converting enzyme inhibitors, aspirin, lipid-lowering medications, cholesterol, LDL cholesterol, HDL cholesterol, physical activity, and eGFR. CKD participants with coronary disease at baseline (n=315) were excluded from the final analysis. The group without ECG abnormalities was set as the reference group. To assess for proportional hazard assumption, Schoenfeld residuals were calculated and plotted against time. Schoenfeld residuals did not show a characteristic pattern of association with time. SPSS software, version 18 (SPSS Inc., Chicago, IL), was used for all analyses.
Results
Of 5888 participants enrolled in CHS from 1989 to 2005, 1192 (20.24%) had CKD at baseline. There were 1140 (95.6%) participants with CKD stage 3, 41 (3.4%) with CKD stage 4, and 11 (0.9%) with CKD stage 5. ECG abnormalities were major in 452 (38.8%), minor in 346 (29.7%), and not seen in 367 (31.5%). Twenty-seven participants with missing ECG data at study entry were excluded from the final analysis. Eighteen participants (1.5%) were lost to follow-up; they were more likely to be male and nonwhite and to have a higher body mass index than participants followed in the cohort.
During the mean follow-up of 10.363.8 years, 814 (68.3%) participants died. A cardiac cause of death was identified in 280 participants. Of these deaths, primary arrhythmia represented 23 (8.2%); secondary arrhythmic mechanism, 95 (33.9%); congestive heart failure, 77 (27.5%); cardiac procedure, 13 (4.6%); multiple causes, 50 (17.9%); and unknown cause, 22 (7.9%).
Patient Characteristics
Baseline demographic data, clinical and biochemical characteristics, and medication therapies for the entire cohort by each ECG category are shown in Table 1 . Participants with eGFR , 60 ml/min per 1.73 m 2 had a higher prevalence of major ECG abnormalities than participants with eGFR $ 60 ml/min per 1.73 m 2 (38.8% versus 27.8%; P,0.001).
CKD participants had a median age of 74.7 years, 631 (52.9%) were female, and 1095 (91.9%) were white. The median (interquartile range) eGFR was 52.8 (46.0-57.9) ml/min per 1.73 m 2 . Only 52 (4.4%) participants had eGFR , 30 ml/min per 1.73 m 2 . The overall prevalence of diabetes and hypertension in CKD participants was higher in patients with major ECG abnormalities: 393 (88.3%) and 105 (23.2%), respectively ( Table 1) .
The types of ECG abnormalities by eGFR and by the presence of CAD at baseline are presented in Table 2 . Ventricular conduction delay and left ventricular hypertrophy were the most prevalent major and minor ECG abnormalities in CKD participants (12.3% and 28.9%).
Participants with CKD were more likely to have major ECG abnormalities (odds ratio, 1.23 [95% CI, 1.06-1.43], adjusted for age, race, gender, diabetes, hypertension, lipid profile, smoking, history of CAD, and angiotensinconverting enzyme inhibitor or b-blocker use) than participants without CKD. The same direction of association was seen for minor ECG abnormalities but was statistically significant (odds ratio, 1.12 [95% CI, 0.97-1.29]). Table 3 summarizes the primary analysis of cardiovascular death, cardiovascular events, and death from any cause by ECG abnormalities in patients with CKD.
Primary Outcomes
The group without ECG abnormalities was taken as the reference group. The first model, unadjusted for covariates, shows an HR of 2.93 (95% CI, 2.30-3.73) for cardiovascular events, 2.60 (95% CI, 1.81-3.73) for cardiovascular death, and 2.46 (95% CI, 2.00-3.02) for overall death in participants with major ECG abnormalities. Adjusted proportional hazards models confirm that compared with the CKD participants without ECG abnormalities, participants with major ECG abnormalities were more likely to die of any cause, have a cardiovascular event, or die of a cardiac cause. Among participants with CKD, coronary bypass surgery was done in 77 (6.6%) and coronary angioplasty in 24 (2.1%); 97 (8.1%) patients with CKD had a stroke.
There was no significant interaction by race or gender. Kaplan-Meier survival curves showed a significantly higher probability (P,0.01) of fatal and nonfatal cardiovascular events for CKD participants with major ECG abnormalities (Figure 1 ).
Secondary Analyses
A separate Cox regression analysis was conducted on the entire CHS population (5888 participants) to assess the interaction between ECG abnormalities and eGFR. There were no statistically significant interactions for minor or major ECG abnormalities (P=0.11 and P=0.22 for cardiovascular mortality; P=0.71 and P=0.12 for cardiovascular events; and P=0.48 and P=0.11 for death, respectively).
To further quantify the risk conferred by specific ECG abnormalities in CKD, we conducted additional Cox analyses. Patients with CKD who had a long QT interval had a 61% higher risk for cardiovascular events (HR, 
Discussion
Our study evaluated the prevalence and prognostic significance of ECG abnormalities in a well defined multiracial United States cohort of patients with CKD. We report that major and minor ECG abnormalities are commonly present in patients with CKD. Of note, the presence of major ECG abnormalities is a robust independent predictor of cardiovascular and overall death and of nonfatal cardiovascular events in patients with CKD.
The observed association is consistent with previous reports (3, (10) (11) (12) . Left ventricular hypertrophy, intraventricular conduction delay, QT prolongation, wide QRS, and atrial fibrillation are the most common ECG abnormalities studied in the literature in conjunction with CKD (13,21,22) . This study extends the findings of Kestenbaum et al. (10) , who demonstrated that longer QRS and corrected QT intervals were independently associated with incident heart failure, CAD, and death among participants with early CKD and those without CKD. The analysis in that study focused on conduction abnormalities; therefore, participants with a history of heart failure, CAD, atrial fibrillation, or implantable pacemakers or those who were using class Ia or class IIIa antiarrhythmic medications were excluded. Our study expands these associations by also evaluating the ECG markers of ischemia (Q waves, ST-T segment changes), combined with markers of rhythm disturbances (atrial fibrillation, first-degree atrioventricular block) and conduction delay. The added benefit of this study is the evaluation of specific effect of ECG findings on cardiovascular mortality. We included all patients with CKD enrolled in CHS; therefore, the sample size was nearly double and the follow-up time was longer (10.3 years versus 9.2 years) compared with those of the previous study. Consequently, the present study was powered to detect a statistically significant effect of major ECG abnormalities on overall mortality, cardiovascular mortality, and events. Significantly, after exclusion of patients with CAD at study entry, we found the same solid independent association of major ECG abnormalities with the outcomes of interest. In summary, this analysis shows that ischemic, rhythm, and conduction abnormalities are more prevalent in patients with CKD and predict a higher rate of incident cardiovascular mortality and events. These findings have important clinical and research implications. ECGs are convenient, inexpensive, and widely available. Although all patients with CKD are recognized as having higher cardiovascular risk (20) , these data allow further risk stratification. Patients with CKD who have major ECG abnormalities may be identified as having a particularly high risk for future cardiovascular events, thereby allowing focused interventions that target known cardiovascular risk reduction. Recently, models that predict progression to ESRD in CKD have been proposed (23) . Our data support the use of ECG abnormalities in the development of predictive models for cardiovascular risk in a CKD population. In addition, clinical trials that test novel approaches and agents to reduce cardiovascular risk in CKD are now being designed. The presence of major ECG abnormalities can be used to identify a subset of patients with CKD who would probably have high cardiovascular event rates, a characteristic that would help facilitate the design and conduct of a clinical trial aimed at reducing cardiovascular risk.
The strengths of our study lie in the use of a populationbased cohort with a solid study design, precise measurements of ECG abnormalities, clear definition of cardiovascular risk factors, formally adjudicated cardiovascular events and mortality, and minimal loss to follow-up over a long period. However, some limitations must be considered. The study population is limited to elderly men and women, most of whom (91.9%) were white. As such, results may not be generalizable to a different population. A separate analysis by individual type of ECG abnormality in a CKD population could be done only for long QT, ventricular conduction delay, and minor isolated ST-T changes, given the small representation of participants in other ECG categories (second-degree atrioventricular block [n=0], complete atrioventricular block [n=1], Wolff-Parkinson-White A limited number of patients with CKD had eGFR , 30 ml/min per 1.73 m 2 ; therefore, inference of ECG abnormalities associated with more advanced renal dysfunction cannot be made. There was no information on duration of CKD at study entry. We calculated eGFR according to the MDRD formula, considering a single baseline creatinine measurement; that might approach lead to misrepresentation of CKD population. Although the MDRD formula was not initially validated in people older than age 70 years, recent studies have reported on its performance in elderly patients (24) .
Finally, not all ECG Minnesota codes were captured in the CHS dataset, to allow for more in-depth analysis of ECG abnormalities. In addition, different studies may vary with regard to the specific ECG classification into major and minor abnormalities (25) (26) (27) (28) (29) . The nomenclature of major and minor ECG abnormalities used in this study, although consistent with other publications from the CHS (30,31), does not reflect the current classification according to the Minnesota criteria (32) . Current guidelines include other ECG measures (such as complete or intermittent left bundle-branch block, complete or intermittent right bundle-branch block, right bundle-branch block with left anterior hemiblock, Brugada pattern, Wolff-Parkinson-White syndrome, artificial pacemaker, ventricular fibrillation or ventricular asystole, incomplete left bundle-branch block, wandering pacemaker, and left atrial enlargement) to determine whether major or minor ECG abnormalities exist. These ECG variables are not available in the CHS dataset; therefore, we are not able to determine whether classification into major and minor ECG changes that incorporates these variables carries the same prognostic significance reported here. This may be subject of future research using more contemporary cohorts.
We believe that this paper highlights the specific ECG findings that confer increased cardiovascular risk and serve as an important risk stratification tool in patients with CKD.
In conclusion, there is a high prevalence of major ECG abnormalities in patients with CKD (eGFR,60 mL/min per 1.73 m 2 ). Furthermore, in elderly patients with CKD, certain major ECG abnormalities predict a significantly higher risk for death and adverse cardiovascular outcomes.
